NASDAQ:ARCT - Arcturus Therapeutics Stock Price, Forecast & News

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics Ltd (NASDAQ:ARCT) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.32. The biotechnology company earned $3.32 million during the quarter, compared to analysts' expectations of $7.60 million. Arcturus Therapeutics had a negative net margin of 63.05% and a negative return on equity of 160.16%. View Arcturus Therapeutics' Earnings History.

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Arcturus Therapeutics.

5 brokers have issued twelve-month target prices for Arcturus Therapeutics' stock. Their forecasts range from $18.00 to $18.00. On average, they expect Arcturus Therapeutics' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 62.9% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

News headlines about ARCT stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Arcturus Therapeutics.

Some companies that are related to Arcturus Therapeutics include Frequency Therapeutics (FREQ), Homology Medicines (FIXX), Omeros (OMER), Akero Therapeutics (AKRO), Flexion Therapeutics (FLXN), TherapeuticsMD (TXMD), DiaMedica Therapeutics (DMCAF), ImmunoGen (IMGN), Vectura Group (VEGPF), Cara Therapeutics (CARA), Urogen Pharma (URGN), AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF) and Crinetics Pharmaceuticals (CRNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Energy Transfer LP Unit (ET), Corbus Pharmaceuticals (CRBP), KLA (KLAC), Abeona Therapeutics (ABEO), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Terravia (TVIAQ), Corcept Therapeutics (CORT) and Exelixis (EXEL).

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARCT stock can currently be purchased for approximately $11.05.

Arcturus Therapeutics has a market capitalization of $167.27 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.

The official website for Arcturus Therapeutics is http://www.arcturusrx.com/.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]